Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5660851 | 0.84 | NR1H2 (0.51) | ESR2NR1H2GPR119NPC1RAB9A | |
| SCHEMBL5662803 | 0.84 | NR1H2 (0.47) | ESR2NR1H2GPR119NPC1RAB9A | |
| SCHEMBL5168466 | 0.84 | NR1H2 (0.47) | ESR2NR1H2GPR119NPC1RAB9A | |
| SCHEMBL5662595 | 0.82 | ESR2 (0.44) | ESR2NR1H2GPR119NPC1RAB9A | |
| SCHEMBL5661667 | 0.82 | ESR2 (0.44) | ESR2NR1H2GPR119NPC1RAB9A | |
| SCHEMBL5662752 | 0.82 | GPR119 (0.45) | ESR2NR1H2GPR119NPC1RAB9A | |
| SCHEMBL5171207 | 0.82 | ESR2 (0.46) | ESR2NR1H2GPR119NPC1RAB9A | |
| SCHEMBL5662883 | 0.81 | ESR2 (0.43) | ESR2NR1H2GPR119NPC1RAB9A | |
| SCHEMBL5661913 | 0.80 | GPR119 (0.47) | ESR2NR1H2GPR119NPC1RAB9A | |
| SCHEMBL5660144 | 0.80 | ESR2 (0.48) | ESR2NR1H2GPR119NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | ESR2 938/4885NR1H2 354/4885GPR119 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.